CSIMarket


Organogenesis Holdings Inc   (NASDAQ: ORGO)
Other Ticker:  
 

Organogenesis Holdings Inc

ORGO's Fundamental analysis








Looking into Organogenesis Holdings Inc growth rates, revenue grew by 6.12 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1853

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Organogenesis Holdings Inc 's net income grew by 289.36 % in III. Quarter 2024 year on year, above company average,

More on ORGO's Growth


Organogenesis Holdings Inc
realized a net loss in trailing twelve months.

Organogenesis Holdings Inc realized cash reduction of $ -0.03 per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.02.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.


More on ORGO's Valuation
 
 Total Debt (Millions $) 62
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 527,886
 Net Income/Employee (TTM) $ -8,563
 Receivable Turnover (TTM) 4.72
 Tangible Book Value (Per Share $) 1.77

Organogenesis Holdings Inc
realized net loss in trailing twelve months.

Organogenesis Holdings Inc realized cash outflow of $ -0.03per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.02.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.

Organogenesis Holdings Inc Price to Book Ratio is at 1.66 lower than Industry Avg. of 88.81. and higher than S&P 500 Avg. of 0.02

More on ORGO's Valuation

  Market Capitalization (Millions $) 463
  Shares Outstanding (Millions) 134
  Employees 862
  Revenues (TTM) (Millions $) 455
  Net Income (TTM) (Millions $) -7
  Cash Flow (TTM) (Millions $) -4
  Capital Exp. (TTM) (Millions $) -10
  Total Debt (Millions $) 62
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 527,886
  Net Income/Employee(TTM) $ -8,563
  Receivable Turnover Ratio (TTM) 4.72
  Tangible Book Value (Per Share $) 1.77

  Market Capitalization (Millions $) 463
  Shares Outstanding (Millions) 134
  Employees 862
  Revenues (TTM) (Millions $) 455
  Net Income (TTM) (Millions $) -7
  Cash Flow (TTM) (Millions $) -4
  Capital Exp. (TTM) (Millions $) -10


    ORGO's Profitability Comparisons
Organogenesis Holdings Inc achieved increase in profitability, due to cost control. Operating Margin grew in III. Quarter 2024 to 5.42 %.

Organogenesis Holdings Inc net profit margin of 10.71 % is currently ranking no. 43 in Major Pharmaceutical Preparations industry, ranking no. 111 in Healthcare sector and number 1261 in S&P 500.


Profitability by Segment
Total 10.71 %



  Ratio
   Capital Ratio (MRQ) 3.09
  Total Debt to Equity (MRQ) 0.22
  Tangible Leverage Ratio (MRQ) 0.71
  Asset Turnover Ratio (TTM) 1.08
  Inventory Turnover Ratio (TTM) 4.09



Organogenesis Holdings Inc achieved increase in profitability, due to cost control. Operating Margin grew in III. Quarter 2024 to 5.42 %.

Organogenesis Holdings Inc net profit margin of 10.71 % is currently ranking no. 43 in Major Pharmaceutical Preparations industry, ranking no. 111 in Healthcare sector and number 1261 in S&P 500.

More on ORGO's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com